Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 5, 2006, Pages 915-920

  Wiley, Dorothy J ^a,c   Wiesmeier, Edward ^b,c   Masongsong, Emmanuel ^a   Gylys, Karen H ^a   Koutsky, Laura A ^d   Ferris, Daron G ^e   Barr, Eliav ^f   Rao, Jian Yu ^b  

^a Acute Care Section   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAMNESIS; ARTICLE; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; LABORATORY TEST; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SQUAMOUS EPITHELIUM; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VAGINA CYTOLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LOGISTIC MODELS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RADIOIMMUNOASSAY; RISK FACTORS; SMOKING; UTERINE CERVICAL NEOPLASMS;

EID: 33744756691     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0963     Document Type: Article

References (48)

1. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-63.
2. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
3. U.S. Centers for Disease Control Division of STD Prevention. Sexually transmitted disease surveillance 1995. Atlanta: Centers for Disease Control and Prevention, U.S. Department of Health Services, Public Health Service; 1996.
4. Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. The hidden epidemic: confronting sexually transmitted diseases. Washington (DC): National Academy Press; 1997.
5. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002;186:1396-402.
6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
7. Bosch FX, Manos MM, Munoz N, et al; International biological study on cervical cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
8. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000;19:1-5.
9. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
10. Hocke C, Leroy V, Morlat P, et al; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GESCA). Cervical dysplasia and human immunodeficiency virus infection in women: prevalence and associated factors. Eur J Obstet Gynecol Reprod Biol 1998;81:69-76.
11. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
12. Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002;95:2145-51.
13. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 2001;84:1219-26.
14. Hiroshima K, Iyoda A, Shibuya K, et al. Evidence of neoangiogenesis and an increase in the number of proliferating cells within the bronchial epithelium of smokers. Cancer 2002;95:1539-45.
15. Harris TG, Kulasingam SL, Kiviat NB. Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol 2004;159:834-42.
16. Ali S, Astley SB, Sheldon TA, Peel KR, Wells M. Detection and measurement of DNA adducts in the cervix of smokers and non-smokers. Int J Gynecol Cancer 1994;4:188-93.
17. Prokopczyk B, Trushin N, Leszczynska J, Waggoner SE, El-Bayoumy K. Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways. Carcinogenesis 2001;22:107-14.
18. Bonassi S, Neri M, Lando C, et al. Effect of smoking habit on the frequency of micronuclei in human lymphocytes: results from the Human MicroNucleus project. Mutat Res 2003;543:155-66.
19. Smith KR, Uyeminami DL, Kodavanti UP, Crapo JD, Chang LY, Pinkerton KE. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med 2002;33:1106-14.
20. Wang LE, Cheng L, Spitz MR, Wei Q. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003;42:1-8.
21. Hoser G, Domagala-Kulawik J, Droszcz P, Droszcz W, Kawiak J. Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med Sci Monit 2003;9:BR310-5.
22. + T cells. Am Rev Respir Dis 1993;148:237-40.
23. Mili F, Flanders WD, Boring JR, Annest JL, Destefano F. The associations of race, cigarette smoking, and smoking cessation to measures of the immune system in middle-aged men. Clin Immunol Immunopathol 1991;59:187-200.
24. Hughes DA, Haslam PL, Townsend PJ, Turner-Warwick M. Numerical and functional alterations in circulatory lymphocytes in cigarette smokers. Clin Exp Immunol 1985;61:459-66.
25. Schaberg T, Theilacker C, Nitschke OT, Lode H. Lymphocyte subsets in peripheral blood and smoking habits. Lung 1997;175:387-94.
26. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
27. Kurman RJ, Solomon D. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: definitions, criteria, and explanatory notes for terminology and specimen adequacy. New York: Springer-Verlag; 1994.
28. Palker TJ, Monteiro JM, Martin MM, et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 2001;19:3733-43.
29. Lowe RS, Brown DR, Bryan JT, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997;176:1141-5.
30. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
31. SAS Institute Inc. SAS language: reference, version 8. Cary: SAS Institute Inc; 1999.
32. Onda T, Carter JJ, Koutsky LA, et al. Characterization of IgA response among women with incident HPV 16 infection. Virology 2003;312:213-21.
33. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-8.
34. Ylitalo N, Josefsson A, Melbye M, et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000;60:6027-32.
35. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia [see comments]. J Natl Cancer Inst 1995;87:1365-71.
36. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69:364-8.
37. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
38. Herd K, Fernando GJ, Dunn LA, Frazer IH, Lambert P, Tindle RW. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein. Virology 1997;231:155-65.
39. Frazer IH, Leippe DM, Dunn LA, et al. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res 1995;55:2635-9.
40. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
41. Dosemeci M, Wacholder S, Lubin JH. Does nondifferential misclassification of exposure always bias a true effect toward the null value? Am J Epidemiol 1990;132:746-8.
42. Saatci E, Inan S, Bozdemir N, Akpinar E, Ergun G. Predictors of smoking behavior of first year university students: questionnaire survey. Croat Med J 2004;45:76-9.
43. Lau EM, Lee P, Lynn H, Sham A, Woo J. The epidemiology of cigarette smoking in Hong Kong Chinese women. Prev Med 2003;37:383-8.
44. Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987-1999. Int J Cancer 2003;106:771-83.
45. Fang X, Li X, Stanton B, Dong Q. Social network positions and smoking experimentation among Chinese adolescents. Am J Health Behav 2003;27:257-67.
46. Chan-Yeung M, Koo LC, Ho JC, et al. Risk factors associated with lung cancer in Hong Kong. Lung Cancer 2003;40:131-40.
47. Sinha DN, Gupta PC, Pednekar MS. Tobacco use among school personnel in eight North-eastern states of India. Indian J Cancer 2003;40:3-14.
48. Kwamanga DH, Odhiambo JA, Amukoye EI. Prevalence and risk factors of smoking among secondary school students in Nairobi. East Afr Med J 2003;80:207-12.